BioCryst Shares Plunge on Disappointing Drug Data
By: Reuters
BioCryst Pharmaceuticals announced disappointing results of a mid-stage clinical trial for its bird flu treatment peramivir, sending shares down sharply in after-hours trading.
The Birmingham, Ala.-based company said preliminary results from a Phase II clinical trial of influenza patients were not statistically significant.
The stock was down at $7.60 in electronic trade after closing on the Nasdaq at $11.78.
BioCryst Pharmaceuticals announced disappointing results of a mid-stage clinical trial for its bird flu treatment peramivir, sending shares down sharply in after-hours trading.
